Top Markets
Coin of the day
Orexo AB (publ) Orexo AB (publ)

Orexo AB (publ)

ORXOF
株式のランク #24986
Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on... Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on the innovation, advancement, and marketing of both conventional medicines and digital therapeutic solutions. Its commercial reach extends across the United States, Europe, and the United Kingdom. The firm's existing line of pharmaceutical products includes Zubsolv tablets, which are prescribed for addressing opioid dependence; Abstral, used to manage acute breakthrough pain in cancer patients; and Edluar, formulated for the brief treatment of insomnia. Looking to its future offerings, Orexo is actively progressing several developmental candidates: OX124, an emergency medication for naloxone rescue; OX125, an intervention for nalmefene rescue; OX640, a potential treatment for allergic reactions; and OX338, a sublingual ketorolac tablet designed for moderate to severe pain relief. Furthermore, the company is engaged in the OX-MPI program, which aims to tackle microvascular diseases often linked with chronic inflammatory conditions. Beyond traditional drugs, Orexo provides a selection of digital health therapies, such as deprexis, a program tailored for treating mild to severe depression; vorvida, targeted at alcohol use disorder; and modia, a digital tool for managing opioid use disorder. Established in 1994, Orexo AB (publ) operates from its primary corporate offices located in Uppsala, Sweden.
株価
$1.55
最終同期: 2026-08-19
時価総額
$54.45M
変化(1日)
0.00%
変化(1年)
-23.27%
SE
取引 Orexo AB (publ) (ORXOF)

カテゴリー

Orexo AB (publ)(ORXOF)の配当利回りの履歴
Orexo AB (publ)(銘柄コード: ORXOF)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Orexo AB (publ)(ORXOF)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)